FRAMINGHAM, MA--(MARKET WIRE)--Dec 10, 2008 -- Symbollon Pharmaceuticals, Inc. (OTC BB:SYMBA.OB - News) announced that on December 8, 2008 it signed a sale/license agreement with BioCide Pharma, Inc. covering upper respiratory tract products based on Symbollon's proprietary iodine-based technology. Under the agreement, Symbollon will transfer ownership of its patent application covering use of its technology in the upper respiratory tract. As partial consideration under the agreement, Symbollon will receive an equity position in BioCide equal to 50% ownership of the company.
